Deborah S Hasin1, Jacob Borodovsky2, Dvora Shmulewitz3, Claire Walsh4, Ofir Livne5, Cara A Struble6, Efrat Aharonovich7, David S Fink8, Alan Budney9. 1. Department of Psychiatry, Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA; Department of Epidemiology, Columbia University Mailman School of Public Health, 722 W 168th St, New York, NY 10032, USA. Electronic address: deborah.hasin@gmail.com. 2. Department of Psychiatry, Dartmouth Geisel School of Medicine, One Medical Center Drive, Lebanon, NH 03756, USA. Electronic address: jacob.t.borodovsky@dartmouth.edu. 3. Department of Psychiatry, Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: dvora.shmulewitz@gmail.com. 4. New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: claire.walsh@nyspi.columbia.edu. 5. Department of Psychiatry, Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: ol2166@cumc.columbia.edu. 6. Department of Psychiatry, Dartmouth Geisel School of Medicine, One Medical Center Drive, Lebanon, NH 03756, USA. Electronic address: cara.a.struble@dartmouth.edu. 7. Department of Psychiatry, Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: efrat.aharonovich@nyspi.columbia.edu. 8. New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: david.fink@nyspi.columbia.edu. 9. Department of Psychiatry, Dartmouth Geisel School of Medicine, One Medical Center Drive, Lebanon, NH 03756, USA. Electronic address: alan.budney@dartmouth.edu.
Abstract
BACKGROUND: Highly-potent cannabis products, e.g., concentrates, entail greater risks of cannabis-related harms than lower-potency products such as plant or flower material. However, little information is available on whether individuals in U.S. states with recreational cannabis laws (RCL) or medical cannabis laws (MCL) are more likely than individuals in U.S. states without cannabis legalization (no-CL) to use highly-potent forms of cannabis. METHODS: Cannabis-using adults in a 2017 online survey (N = 4064) provided information on state of residence and past-month cannabis use, including types of products used, categorized as low-potency (smoked or vaped plant cannabis) or high-potency (vaping or dabbing concentrates). Multivariable logistic regression models generated adjusted odds ratios (aOR) and 95% confidence intervals (CI) for use of high-potency cannabis products by state cannabis legalization status (RCL, MCL, no-CL). RESULTS: Compared to participants in no-CL states, participants in RCL states had greater odds of using high-potency concentrate products (aOR=2.61;CI=1.77-3.86), as did participants in MCL-only states (aOR=1.55;CI=1.21-1.97). When participants in RCL states and MCL states were directly compared, those in RCL states had greater odds of using high-potency concentrate products (aOR=1.69;CI=1.27-2.42). DISCUSSION: Although the sample was not nationally representative and the cross-sectional data precluded determining the direction of effect, results suggest that use of high-potency cannabis concentrates is more likely among those in RCL states. Clinicians in RCL states should screen cannabis users for harmful patterns of use. Policymakers in states that do not yet have RCL should consider these findings when drafting new cannabis laws, including the specific products permitted and how best to regulate them.
BACKGROUND: Highly-potent cannabis products, e.g., concentrates, entail greater risks of cannabis-related harms than lower-potency products such as plant or flower material. However, little information is available on whether individuals in U.S. states with recreational cannabis laws (RCL) or medical cannabis laws (MCL) are more likely than individuals in U.S. states without cannabis legalization (no-CL) to use highly-potent forms of cannabis. METHODS: Cannabis-using adults in a 2017 online survey (N = 4064) provided information on state of residence and past-month cannabis use, including types of products used, categorized as low-potency (smoked or vaped plant cannabis) or high-potency (vaping or dabbing concentrates). Multivariable logistic regression models generated adjusted odds ratios (aOR) and 95% confidence intervals (CI) for use of high-potency cannabis products by state cannabis legalization status (RCL, MCL, no-CL). RESULTS: Compared to participants in no-CL states, participants in RCL states had greater odds of using high-potency concentrate products (aOR=2.61;CI=1.77-3.86), as did participants in MCL-only states (aOR=1.55;CI=1.21-1.97). When participants in RCL states and MCL states were directly compared, those in RCL states had greater odds of using high-potency concentrate products (aOR=1.69;CI=1.27-2.42). DISCUSSION: Although the sample was not nationally representative and the cross-sectional data precluded determining the direction of effect, results suggest that use of high-potency cannabis concentrates is more likely among those in RCL states. Clinicians in RCL states should screen cannabis users for harmful patterns of use. Policymakers in states that do not yet have RCL should consider these findings when drafting new cannabis laws, including the specific products permitted and how best to regulate them.
Authors: Qiana L Brown; Aaron L Sarvet; Dvora Shmulewitz; Silvia S Martins; Melanie M Wall; Deborah S Hasin Journal: JAMA Date: 2017-01-10 Impact factor: 56.272
Authors: Silvia S Martins; Christine M Mauro; Julian Santaella-Tenorio; June H Kim; Magdalena Cerda; Katherine M Keyes; Deborah S Hasin; Sandro Galea; Melanie Wall Journal: Drug Alcohol Depend Date: 2016-10-11 Impact factor: 4.492
Authors: Lindsey A Hines; Tom P Freeman; Suzanne H Gage; Stanley Zammit; Matthew Hickman; Mary Cannon; Marcus Munafo; John MacLeod; Jon Heron Journal: JAMA Psychiatry Date: 2020-10-01 Impact factor: 21.596
Authors: Ofir Livne; Alan Budney; Jacob Borodovsky; Claire Walsh; Dvora Shmulewitz; David S Fink; Cara A Struble; Mohammad Habib; Efrat Aharonovich; Deborah S Hasin Journal: Addict Behav Date: 2022-05-23 Impact factor: 4.591